Investment Info

Urologix, Inc., based in Minneapolis, is the leading provider for in-office BPH therapy. The company develops, manufactures, markets and distributes minimally invasive medical products for BPH treatment. Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.

Urologix' patented Cooled ThermoTherapy™ technology is creating effective treatment options for a wide range of patients with BPH. Cooled ThermoTherapy delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue and enhances patient comfort.

Prostiva® RF Therapy provides direct visualization with 360 degrees of precision which allows the urologist to treat the median and lateral lobe as well as asymmetrical prostates. This system is able to reach intraprostatic temperatures of 110°C allowing it to create a lesion in the tissue causing significant necrosis in just two minutes and 20 seconds. Experienced physicians report good patient tolerability with the utilization of a prostate block.

Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

¹Data on file at Urologix, Inc.

Stock Quote
ULGX (Common Stock)
ExchangeOTCQB (US Dollar)
Financial Status IndicatorN
Change (%) Stock is Up 0.01 (12.50%)
Data as of 04/06/15 9:56 a.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
Download Documentation 2014 Annual Report
Recent NewsMore >>
03/23/15Urologix Announces Hiring of Chief Financial Officer
MINNEAPOLIS, March 23, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the appointment of Scott M. Madson as its Chief Financial Officer effective April 1, 2015. Mr. Madson brings over 30 years of both public and private company financial leadership experience to his new role, having most recently provided finance and accounting management consulting services through his compa... 
Printer Friendly Version
02/05/15Urologix Reports Second Quarter Fiscal Year 2015 Results
Recent Quarter Highlights Revenue $3.1 Million, 2% increase from first quarter fiscal year 2015. Net loss reduced by 67% to $357,000 from a net loss of $1.1 million in the second quarter of fiscal year 2014 and 18% lower than first quarter net loss of $437,000. Total cash balances, including restricted cash, increased $25,000 compared to first quarter fiscal year 2015 ending cash balances. MINNEAPOLIS, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the le... 
Printer Friendly Version
01/29/15Urologix to Host Its Fiscal Year 2015 Second Quarter Conference Call
MINNEAPOLIS, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX) will host a conference call to present second quarter fiscal year 2015 results on Thursday, February 5, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-515-2910 and enter the Participant Passcode 37953871 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at Greg Fluet, Chie... 
Printer Friendly Version
01/12/15Urologix Reports Preliminary Fiscal Year 2015 Second Quarter Revenue and Cash Results
Second quarter preliminary revenue of $3.1M, up 2% sequentially MINNEAPOLIS, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announces preliminary revenue and cash balances for its second quarter of fiscal year 2015 ended December 31, 2014. Second quarter of fiscal year 2015 revenue is expected to be approximately $3.1 million, up approximately 2% sequentially from the first ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Urologix, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.